查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1857756

按檢測類型、應用領域和最終用戶分類的微量殘存疾病檢測市場 - 全球預測 2025-2032

Minimal Residual Disease Testing Market by Test Type, Application Areas, End-User Vertical - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，微量殘存疾病檢測市場規模將達到 44.7 億美元，複合年成長率為 11.47%。

關鍵市場統計數據
基準年 2024 18.7億美元
預計年份：2025年 20.8億美元
預測年份 2032 44.7億美元
複合年成長率 (%) 11.47%

微量殘存疾病（MRD）檢測已從一項專門的研究性檢測發展成為一項重要的臨床工具，它能夠為血液腫瘤和固態腫瘤的預後評估、治療強度指導以及適應性治療策略的製定提供資訊。臨床醫生和實驗室負責人現在不僅將MRD視為一種生物標記物，更將其視為一種決策工具，它影響著緩解評估、復發監測以及新治療方法的合格。因此，診斷實踐正在採用更廣泛的分析方法、更高的靈敏度閾值以及旨在將檢測結果整合到快速變化的臨床路徑中的工作流程。

更靈敏的檢測平台的引入以及臨床試驗終點與微小殘留病（MRD）狀態的一致性正在加速MRD檢測的臨床應用，同時，樣本處理、品管和報告標準的同步進步也開始降低實驗室間的差異。因此，MRD檢測正處於臨床緊迫性和技術創新的交匯點：它必須在影響治療方法選擇的時間範圍內提供可重複的、具有臨床意義的結果。因此，對於那些希望將MRD檢測從專科中心推廣到常規實踐的相關人員，了解分析能力、臨床驗證和操作準備之間的相互作用至關重要。

分析創新、臨床檢驗以及與治療決策框架的整合將推動微小殘留病灶檢測發生變革性轉變。

隨著高靈敏度分子技術、純化細胞檢測和數位分析的融合，微小殘留疾病（MRD）檢測領域正經歷變革性的轉變。針對低等位基因頻率檢測的標靶化次世代定序儀panel、可實現絕對定量分析的數位PCR方法以及針對標準化免疫表現型分析最佳化的多參數流式細胞技術創新技術，共同提高了MRD的檢測標準。同時，改進的檢體儲存方法、集中式參考檢測以及跨平台檢驗研究正在降低實驗室間差異，並增強臨床醫生對MRD檢測結果的信心。

除了分析技術的進步，將微小殘留病灶（MRD）納入臨床試驗設計和監管路徑正在重塑商業性和臨床獎勵，從實驗室資訊系統到基於雲端基礎的變異解讀等數位化基礎設施，支援更快的結果交付和互聯分析，從而實現可擴展的臨床決策支援。這些轉變正在加速MRD從一種小眾診斷方法轉向精準腫瘤學工作流程中標準化要素的轉變。

評估美國2025年關稅政策調整對供應鏈成本結構及臨床取得微小殘留疾病診斷的累積影響

2025年生效的關稅調整為依賴全球一體化供應鏈獲取儀器、試劑和耗材的相關人員帶來了新的營運複雜性。進口專用設備和檢測組件的關稅提高將增加單位成本，並促使獎勵調整籌資策略。對於臨床實驗室和診斷試劑生產商而言，這些成本壓力可能導致淨利率下降、高成本設備的更新換代週期延長，以及需要重新評估定價和服務模式以在不影響臨床應用的前提下維持生存。

除了直接的成本影響外，關稅還會造成供應鏈摩擦，延長關鍵試劑和備件的前置作業時間。延長的補貨週期將加劇高通量檢測中心的庫存風險，迫使實驗室實現供應商多元化，或對依賴在地採購原料的替代檢測方法合格。政策應對措施和商業性緩解措施正在陸續訂定。一些機構正在加快對區域製造的投資，而另一些機構則在協商長期供應協議以分散關稅風險。同時，資源有限的醫院和診斷網路可能面臨先進微生物鑑定平台的延遲或取得受限。因此，相關人員在預測技術採用時間表和設計穩健的營運模式時，必須考慮關稅引起的成本和可用性變化。

關鍵細分洞察揭示了檢測方式的臨床應用和最終用戶垂直領域如何共同決定其採用優先順序和價值創造。

從細分觀點出發，我們可以看到分析方法、臨床適應症和最終用戶類型如何相互作用，從而影響微小殘留疾病（MRD）檢測的普及路徑和價值創造。染色體微陣列細胞遺傳學和螢光原位雜合技術（FISH）等檢測方法在某些血液學領域發揮著重要的結構異常檢測作用，它們與流式細胞流式細胞技術方法並存，其中多參數和單參數平台提供了互補的細胞解析度。分子檢測方法佔據核心地位。標靶化次世代定序儀panel和全基因組定序為基於突變的MRD評估提供了靈敏度和廣度，而數位PCR和定量PCR則可快速、經濟高效地對預定義標靶進行定量。

應用領域進一步決定了哪些技術方案應優先考慮。白血病亞型，包括急性淋巴性白血病、急性骨髓性白血病和慢性淋巴性白血病，均採用分子檢測和免疫表現型檢測來正交確認緩解狀態。淋巴瘤檢測涵何傑金氏病和非何傑金氏病淋巴瘤，需要客製化的檢測設計，以平衡靈敏度和腫瘤異質性。多發性骨髓瘤和某些固態瘤，例如乳癌和大腸癌，需要客製化的微小殘留疾病（MRD）檢測策略，以反映疾病生物學和可用的治療方案。最後，最終用戶——學術機構、生物製藥公司、診斷實驗室和醫院——各自有著獨特的需求。學術中心優先考慮方法創新和轉化研究，生物製藥公司重視用於臨床試驗的標準化檢測，診斷實驗室重視檢測通量和成本效益，而醫院則優先考慮週轉時間和與電子健康記錄的整合。了解這些相互依存關係，可以更精確地協調產品設計、臨床證據產生和商業模式。

區域戰略情報地圖繪製：美洲、中東和非洲以及亞太地區的採用趨勢、基礎設施優勢、報銷動態和合作生態系統

區域動態對微小殘留病灶（MRD）的部署有顯著影響，因為不同地區的監管系統、報銷框架和實驗室基礎設施差異巨大。在美洲，高密度的成熟參考實驗室和臨床試驗支持新型MRD平台的快速普及，但支付方覆蓋範圍的差異可能會限制其在臨床試驗之外的常規應用。該地區的診斷網路也發揮創新中心的作用，吸引臨床中心和產業界的夥伴關係，從而加速實證醫學證據的產生和應用。

歐洲、中東和非洲的異質性顯而易見：西歐市場受益於整合的報銷機制和完善的實驗室認證體系，而中東和非洲的許多國家則面臨檢測能力不足的問題，限制了先進微小殘留疾病（MRD）檢測的普及。聯合採購安排和區域參考實驗室正逐漸成為彌合這一差距的可行方案。在亞太地區，對本土生產的投資、臨床試驗活動的活性化以及醫院網路的擴張正在推動檢測技術的普及，但監管時間表和當地驗證要求要求必須制定周密的市場准入計畫。綜上所述，這些區域模式表明，商業化策略必須因地制宜。一些地區受益於擴充性的集中式檢測模式，而其他地區則受益於分散式的照護現場和就近檢測方法，這些方法能夠更好地滿足檢測的可及性和靈活性需求。

透過垂直整合夥伴關係關係來塑造競爭地位；各產業關鍵洞察，聚焦在證據生成與服務差異化策略

當前微生物診斷（MRD）領域的競爭格局呈現出專業化融合與整合並存的趨勢。診斷試劑開發商和平台提供者在分析靈敏度、檢測穩健性和臨床工作流程整合便利性方面展開競爭，而試劑供應商則在一致性、批間可靠性和符合監管規定的供應鏈方面展開競爭。平台整合商和臨床實驗室網路正日益提供包含儀器、軟體輔助解讀和報告範本的捆綁式服務，以滿足臨床醫生的決策需求。

診斷公司與生物製藥贊助商之間的合作能夠共同開發用於治療計畫的伴隨微小殘留疾病（MRD）檢測，而與學術中心的合作則可提供檢驗隊列和真實世界證據。與此同時，一些公司正在尋求垂直整合——將檢測開發、生產和臨床服務交付整合到一個平台——以降低供應風險並獲得更大的下游價值。服務差異化不僅體現在分析效能上，也體現在培訓、認證支援和上市後監測能力。透過同儕審查的證據證明其臨床效用的能力，日益成為市場領導者與利基市場參與者之間的分水嶺。這種競爭態勢表明市場正在成熟，與臨床相關人員的策略合作以及卓越的營運將決定長期的成功。

為行業領導者提供切實可行的、優先排序的建議，以降低風險，並協調臨床證據運作和支付方參與，從而加速應用。

致力於加速微小殘留病灶（MRD）應用的行業領導者應採取一系列務實舉措，將臨床效用與營運可行性相結合。首先，應優先產生可靠的臨床證據，將MRD終點納入前瞻性治療試驗，並進行真實世界結果研究，以展示MRD指導的決策如何改變患者的治療軌跡。其次，應透過尋找替代供應商、建立區域庫存緩衝以及考慮在本地生產高風險組件來增強供應鏈韌性，從而降低關稅和物流風險。

第三，儘早與支付者接洽，確保臨床效益體現在報銷路徑中，採用成本效益模型和與臨床適應症相關的分級覆蓋策略。第四，投資建造可互通的數位基礎設施，將實驗室檢測結果與電子健康記錄和決策支援工具連接起來，以減少臨床醫生的工作阻力，並確保及時協調醫療服務。第五，採用靈活的商業模式，例如基於績效的定價和分級服務，以降低資源受限環境下的應用門檻。最後，重視人才隊伍建設，透過標準化的培訓和認證項目，確保分散式偵測環境中偵測效能的一致性。綜上所述，這些措施將有助於在快速發展的診斷環境中，平衡長期策略定位與當前的業務需求。

一項透明的調查方法，描述了用於深入了解微小殘留疾病檢測的資料來源、專家參與、分析框架和檢驗方法。

本分析綜合了來自多方面研究途徑的證據，旨在對研究結果進行三角驗證並減少偏差。調查方法結合了對同行評審文獻、臨床指南、監管文件和技術白皮書的系統性回顧，以及有針對性的初步研究，包括對臨床專家、首席研究員、生物製藥研發負責人和供應鏈專業人員的訪談。在條件允許的情況下，將檢測性能數據與已發表的驗證研究和監管摘要進行比較，以評估其一致性和可重複性。

分析架構包括技術成熟度評估、價值鏈映射和相關人員影響分析，旨在了解瓶頸和機會的交會點。透過情境分析，對區域政策和關稅的影響進行定性建模，並考慮了採購路徑、前置作業時間敏感度和區域製造的可行性。研究結果透過專家評審會議進行迭代檢驗，以協調不同的觀點並突出其局限性。主要調查方法的局限性包括已發布的測試方法文件存在差異、監管指南不斷變化以及未來政策調整存在固有的不確定性。在製定結論和建議時，已明確考慮了這些因素。

總結結論，重點闡述將決定微小殘留病灶診斷未來發展軌跡的機會、營運挑戰和策略重點。

摘要：微小殘留疾病（MRD）檢測正處於關鍵的十字路口，分析技術的進步、臨床檢驗工作和商業性策略正在融合，以實現更廣泛的臨床效用。目前可用的診斷方法提供了一套套件，能夠適應疾病生物學和醫療服務提供方面的限制，但成功的規模化應用將取決於嚴謹的證據生成、穩健的供應鏈以及支付方的積極參與。諸如關稅和不斷變化的報銷制度等政策變化增加了複雜性，需要進行適應性的商業化和營運規劃。

對於整個生態系中的相關人員，協作是未來發展的關鍵。臨床和實驗室機構必須就標準化操作流程達成一致，業界必須投資於可重複的檢測設計和證據，支付方和監管機構必須與申辦方合作，制定將微小殘留病灶（MRD）檢測結果轉化為有意義的臨床決策的路徑。落實這些優先事項將決定MRD能否成為精準腫瘤學中的常規工具，還是仍只能作為一種特殊應用。技術能力與系統層面的準備程度之間的平衡最終將影響患者的治療機會和治療創新。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 液態切片技術在非侵入性殘留病灶監測的應用日益廣泛
  • 數位PCR技術的進步提高了疾病檢測的敏感度。
  • 增加對微小殘留病灶研究的投入，以支持早期治療性介入策略
  • 制定實驗室間微小殘留病灶評估的標準化通訊協定
  • 整合人工智慧工具以提高微小殘留病灶資料的準確性和解讀能力
  • 微小殘留病灶狀態作為骨髓惡性腫瘤預後生物標記的應用日益廣泛
  • 液態切片技術在微量殘存疾病的非侵入性監測中快速應用
  • 重點關注成本效益和可近性，以促進醫療保健系統中微量殘存疾病檢測的廣泛應用。
  • 診斷公司與生物製藥公司在伴隨 MRD 檢測開發的合作
  • 擴大微量殘存疾病檢測在個人化癌症治療的應用

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 依檢測類型分類的微量殘存疾病檢測市場

  • 細胞遺傳學
    • 染色體微陣列
    • 螢光雜合反應螢光（FISH）
  • 流式細胞技術
    • 多參數流式細胞技術
    • 單參數流式細胞技術
  • 次世代定序儀（NGS）
    • 標靶定序
    • 全基因組定序
  • 聚合酵素鏈鎖反應（PCR）
    • 數位PCR
    • 定量PCR

第9章 依應用分類的微量殘存疾病檢測市場

  • 白血病
    • 急性淋巴性白血病（ALL）
    • 急性骨髓性白血病（AML）
    • 慢性淋巴性白血病（CLL）
  • 淋巴瘤
    • 何傑金氏淋巴瘤
    • 非何傑金氏淋巴瘤
  • 多發性骨髓瘤
  • 固體癌
    • 乳癌
    • 大腸直腸癌

第10章 產業微量殘存疾病檢測市場

  • 學術和研究機構
  • 生物製藥公司
  • 診斷實驗室
  • 醫院

第11章 區域性微量殘存疾病檢測市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第12章 按組別分類的微量殘存疾病檢測市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章 各國微量殘存疾病檢測市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Agilus Diagnostics Ltd.
    • Amgen Inc.
    • Adaptive Biotechnologies Corporation
    • ARUP Laboratories
    • AstraZeneca PLC
    • Asuragen Inc. by Bio-Techne Corporation
    • Bio-Rad Laboratories, Inc.
    • Bristol-Myers Squibb Company
    • C2I Genomics Inc.
    • Cergentis BV
    • Exact Sciences Corporation
    • F. Hoffmann-La Roche Ltd.
    • Genetron Holdings Limited
    • GRAIL, LLC by Illumina, Inc.
    • Guardant Health, Inc.
    • Integrated DNA Technologies, Inc.
    • Invivoscribe, Inc.
    • Kite Pharma, Inc. by Gilead Sciences, Inc.
    • Laboratory Corporation of America Holdings
    • Mdxhealth BV
    • MedGenome Inc
    • Mission Bio, Inc.
    • Myriad Genetics, Inc.
    • Natera Inc.
    • NeoGenomics Laboratories, Inc.
    • OPKO Health, Inc.
    • Quest Diagnostics incorporated
    • Sysmex Corporation
    • Veracyte, Inc.
Product Code: MRR-961BA04A2E6C

The Minimal Residual Disease Testing Market is projected to grow by USD 4.47 billion at a CAGR of 11.47% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.87 billion
Estimated Year [2025] USD 2.08 billion
Forecast Year [2032] USD 4.47 billion
CAGR (%) 11.47%

Minimal residual disease (MRD) testing has evolved from a specialized research assay into a pivotal clinical tool that informs prognosis, guides therapeutic intensity, and enables adaptive treatment strategies across hematologic and selected solid tumor indications. Clinicians and laboratory leaders now view MRD not merely as a biomarker but as a decision-making instrument that affects remission assessment, relapse surveillance, and eligibility for novel therapies. Consequently, the diagnostic landscape is responding with a broader array of analytical approaches, enhanced sensitivity thresholds, and workflows designed to integrate results into fast-moving clinical pathways.

The introduction of more sensitive platforms and the alignment of clinical trial endpoints with MRD status have accelerated clinical adoption, while parallel advances in sample handling, quality control, and reporting standards are beginning to reduce variability across testing sites. As a result, MRD testing occupies an intersection of clinical urgency and technological innovation: it must deliver reproducible, clinically actionable results within timelines that influence therapeutic choices. Understanding the interplay between analytical capability, clinical validation, and operational readiness is therefore essential for stakeholders seeking to scale MRD testing from specialized centers to routine care settings.

Transformative shifts redefining minimal residual disease testing driven by analytical innovation clinical validation and integration into therapeutic decision frameworks

The MRD landscape is undergoing transformative shifts driven by convergence between high-sensitivity molecular techniques, refined cellular assays, and digital analytics. Innovations such as targeted next-generation sequencing panels tailored for low-allele-frequency detection, digital PCR approaches that deliver absolute quantitation, and multi-parameter flow cytometry optimized for standardized immunophenotyping are collectively raising the floor of detectability. Concurrently, improvements in sample preservation, centralized reference testing, and cross-platform validation studies are reducing inter-laboratory variance and increasing clinician confidence in MRD readouts.

Beyond raw analytical progress, the integration of MRD into clinical trial design and regulatory pathways is reshaping commercial and clinical incentives. As MRD is increasingly used as an early surrogate endpoint for therapeutic efficacy, sponsors are structuring trials and regulatory engagements to demonstrate how MRD-informed dosing or duration strategies improve patient outcomes. Additionally, digital infrastructure-ranging from laboratory information systems to cloud-based variant interpretation-supports faster result delivery and federated analytics, which in turn enable scalable clinical decision support. Together, these shifts are accelerating MRD from a niche diagnostic towards a standardized element of precision oncology workflows.

Assessing the cumulative effects of United States tariff policy adjustments in 2025 on supply chains cost structures and clinical access to minimal residual disease diagnostics

Tariff changes enacted in 2025 have introduced a new layer of operational complexity for stakeholders that depend on a globally integrated supply chain for instruments, reagents, and consumables. Increased duties on imported specialized equipment and assay components raise unit costs and create incentive pressures to adjust procurement strategies. For clinical laboratories and diagnostic manufacturers, these cost pressures can translate into tighter margins, delayed capital renewal cycles for high-cost instrumentation, and a need to reassess pricing or service models to maintain viability without compromising clinical access.

In addition to direct cost effects, tariffs contribute to supply chain friction that can lengthen lead times for critical reagents and spare parts. Extended replenishment cycles exacerbate inventory risk for high-throughput centers and may compel laboratories to diversify supplier portfolios or to qualify alternative assay formats that rely on locally sourced inputs. Policy responses and commercial mitigations have begun to emerge: some organizations are accelerating regional manufacturing investments, while others are negotiating long-term supply agreements that allocate tariff risk. Clinically, the net effect is uneven; well-resourced systems can absorb short-term disruption through internal buffering and strategic procurement, whereas resource-constrained hospitals and diagnostic networks may face delays or restricted access to advanced MRD platforms. Consequently, stakeholders must factor in tariff-induced cost and availability shifts when projecting technology adoption timelines and when designing resilient operational models.

Key segmentation insights demonstrating how test modalities clinical applications and end-user verticals combine to determine adoption priorities and value creation

A segmentation-aware perspective reveals how analytical modality, clinical indication, and end-user type interact to shape adoption pathways and value creation for MRD testing. Test types such as cytogenetics with chromosomal microarray and FISH retain critical roles for structural aberration detection in certain hematologic contexts, but they coexist with flow cytometry approaches where multi-parameter and single-parameter platforms offer complementary cellular resolution. Molecular modalities occupy a central position: targeted next-generation sequencing panels and whole-genome sequencing provide sensitivity and breadth for mutation-based MRD assessment, while digital PCR and quantitative PCR deliver rapid, cost-efficient quantitation for predefined targets.

Application areas further guide which technical profile is prioritized. In leukemia subtypes including acute lymphoblastic leukemia, acute myeloid leukemia, and chronic lymphocytic leukemia, both molecular and immunophenotypic assays are used to provide orthogonal confirmation of remission status. Lymphoma testing, encompassing Hodgkin's and non-Hodgkin's variants, requires tailored assay designs that balance sensitivity against tumor heterogeneity. Multiple myeloma and selected solid tumors such as breast and colorectal cancer demand bespoke MRD strategies that reflect disease biology and available therapeutic options. Finally, end-user verticals-academic and research institutes, biopharmaceutical companies, diagnostic laboratories, and hospitals-each press unique requirements. Academic centers prioritize methodological innovation and translational research, biopharmaceutical sponsors emphasize standardized assays for clinical trials, diagnostic laboratories focus on throughput and cost-efficiency, and hospitals prioritize turnaround time and integration with electronic medical records. Understanding these interdependencies enables more precise alignment of product design, clinical evidence generation, and commercial models.

Regional strategic intelligence mapping adoption trends infrastructure strengths reimbursement dynamics and collaborative ecosystems across the Americas Europe Middle East & Africa and Asia-Pacific

Regional dynamics exert a strong influence on MRD deployment because regulatory regimes, reimbursement frameworks, and laboratory infrastructure diverge significantly across geographies. In the Americas, established reference laboratories and a high density of clinical trials support relatively rapid uptake of novel MRD platforms, although payer coverage variability can constrain routine use outside of trial settings. The region's diagnostic networks also serve as hubs for innovation, attracting partnerships between clinical centers and industry that accelerate evidence generation and adoption.

Across Europe, the Middle East & Africa, heterogeneity is pronounced: Western European markets benefit from consolidated reimbursement pathways and robust laboratory accreditation systems, while many countries in the Middle East and Africa face capacity constraints that limit access to advanced MRD testing. Collaborative procurement mechanisms and regional reference laboratories are emerging as pragmatic solutions to bridge gaps. In the Asia-Pacific, investment in domestic manufacturing, rising clinical trial activity, and expanding hospital networks are driving uptake, though regulatory timelines and local validation requirements necessitate careful market entry planning. Collectively, these regional patterns imply that commercialization strategies must be tailored: scalable centralized testing models may work in some geographies, whereas decentralized point-of-care or near-patient approaches could better address access and timeliness in others.

Key company-level insights highlighting partnerships vertical integration evidence generation and service differentiation strategies that shape competitive positioning

Contemporary competitive dynamics in the MRD space are characterized by a blend of specialization and integration. Diagnostic developers and platform providers differentiate through analytical sensitivity, assay robustness, and ease of clinical workflow integration, while reagent suppliers compete on consistency, lot-to-lot reliability, and regulatory-compliant supply chains. Platform integrators and clinical laboratory networks are increasingly offering bundled services that combine instrumentation, software-enabled interpretation, and reporting templates that align with clinician decision needs.

Partnership models stand out as an accelerant: collaborations between diagnostic firms and biopharmaceutical sponsors enable co-development of companion MRD assays for therapeutic programs, while alliances with academic centers provide validation cohorts and real-world evidence. In parallel, some organizations are pursuing vertical integration-bringing assay development, manufacturing, and clinical service delivery under one operational umbrella-to reduce supply risk and capture greater downstream value. Service differentiation extends beyond analytical performance to include training, accreditation support, and post-market surveillance capabilities; the ability to demonstrate clinical utility through peer-reviewed evidence increasingly separates market leaders from niche players. These competitive behaviors suggest a maturing market where strategic alignment with clinical stakeholders and operational excellence determine long-term success.

Actionable and prioritized recommendations for industry leaders to accelerate adoption mitigate risk and align clinical evidence operational execution and payer engagement

Industry leaders seeking to accelerate MRD adoption should pursue a pragmatic set of actions that align clinical utility with operational feasibility. First, prioritize robust clinical evidence generation by embedding MRD endpoints into prospective therapeutic trials and by conducting real-world outcome studies that demonstrate how MRD-guided decisions alter patient trajectories. Second, strengthen supply chain resilience by qualifying alternative suppliers, building regional inventory buffers, and exploring localized production for high-risk components to mitigate tariff and logistics exposures.

Third, engage payers early to translate clinical benefit into reimbursement pathways, using cost-effectiveness models and phased coverage strategies tied to clinical indications. Fourth, invest in interoperable digital infrastructure that links laboratory results with electronic medical records and decision-support tools, thereby reducing clinician friction and ensuring timely therapeutic adjustments. Fifth, adopt flexible commercial models such as performance-based pricing or tiered service offerings to lower barriers for adoption in resource-constrained settings. Lastly, commit to workforce development through standardized training and accreditation programs that ensure consistent assay performance across decentralized testing environments. Collectively, these actions balance immediate operational needs with longer-term strategic positioning in a rapidly evolving diagnostic landscape.

Transparent research methodology explaining data sources expert engagements analytical frameworks and validation approaches used to derive insights on minimal residual disease testing

This analysis synthesizes evidence from a multi-pronged research approach designed to triangulate findings and reduce bias. The methodology combined systematic review of peer-reviewed literature, clinical guidelines, regulatory documents, and technical white papers with targeted primary research comprising interviews with clinical experts, laboratory directors, biopharma development leads, and supply chain specialists. Where available, assay performance data was compared across published validation studies and regulatory summaries to assess concordance and reproducibility.

Analytical frameworks included technology readiness assessment, value-chain mapping, and stakeholder impact analysis to understand where bottlenecks and opportunities converge. Regional policy and tariff impacts were modeled qualitatively through scenario analysis that considered procurement pathways, lead-time sensitivity, and the feasibility of regional manufacturing. Findings were iteratively validated through expert review sessions to reconcile divergent perspectives and to highlight limitations. Key methodological limitations include variability in published assay documentation, evolving regulatory guidance, and the inherent uncertainty around future policy adjustments; these factors were explicitly considered when framing conclusions and recommendations.

Concluding synthesis emphasizing the opportunities operational challenges and strategic priorities that will determine the future trajectory of minimal residual disease diagnostics

In summary, MRD testing stands at a pivotal juncture where analytical advances, clinical validation efforts, and commercial strategies converge to enable broader clinical utility. The diagnostic modalities available today collectively offer a toolkit that can be matched to disease biology and care delivery constraints, but successful scale-up depends on rigorous evidence generation, resilient supply chains, and payer engagement. Policy shifts such as tariffs and evolving reimbursement landscapes add complexity, requiring adaptive commercialization and operational planning.

For stakeholders across the ecosystem, the path forward centers on collaboration: clinical sites and laboratories must align on standardized practices, industry must invest in reproducible assay design and evidence, and payers and regulators should work with sponsors to define pathways that translate MRD detection into meaningful clinical decisions. Executing on these priorities will determine whether MRD fulfills its promise as a routine instrument of precision oncology or remains confined to specialized use cases. The balance of technical capability and system-level readiness will ultimately shape patient access and therapeutic innovation.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Growing adoption of liquid biopsy techniques for non-invasive residual disease monitoring
  • 5.2. Advancements in digital PCR technology enhancing sensitivity of disease detection
  • 5.3. Rising investment in research focusing on minimal residual disease to support early treatment intervention strategies
  • 5.4. Development of standardized protocols for minimal residual disease assessment across laboratories
  • 5.5. Integration of artificial intelligence tools to improve accuracy and interpretation of minimal residual disease data
  • 5.6. Increasing use of MRD status as a prognostic biomarker in hematologic malignancies
  • 5.7. Rapid growth in the adoption of liquid biopsy techniques for non-invasive monitoring of minimal residual disease
  • 5.8. Focus on cost-effectiveness and accessibility to broaden the reach of minimal residual disease testing in healthcare systems
  • 5.9. Collaborations between diagnostic firms and biopharma to develop companion MRD tests
  • 5.10. Expanding applications of minimal residual disease testing in personalized cancer therapies

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Minimal Residual Disease Testing Market, by Test Type

  • 8.1. Cytogenetics
    • 8.1.1. Chromosomal microarray
    • 8.1.2. Fluorescence in situ hybridization (FISH)
  • 8.2. Flow Cytometry
    • 8.2.1. Multi-parameter flow cytometry
    • 8.2.2. Single-parameter flow cytometry
  • 8.3. Next-Generation Sequencing (NGS)
    • 8.3.1. Targeted sequencing
    • 8.3.2. Whole genome sequencing
  • 8.4. Polymerase Chain Reaction (PCR)
    • 8.4.1. Digital PCR
    • 8.4.2. Quantitative PCR

9. Minimal Residual Disease Testing Market, by Application Areas

  • 9.1. Leukemia
    • 9.1.1. Acute Lymphoblastic Leukemia (ALL)
    • 9.1.2. Acute Myeloid Leukemia (AML)
    • 9.1.3. Chronic Lymphocytic Leukemia (CLL)
  • 9.2. Lymphoma
    • 9.2.1. Hodgkin's lymphoma
    • 9.2.2. Non-Hodgkin's lymphoma
  • 9.3. Multiple Myeloma
  • 9.4. Solid Tumors
    • 9.4.1. Breast cancer
    • 9.4.2. Colorectal cancer

10. Minimal Residual Disease Testing Market, by End-User Vertical

  • 10.1. Academic & Research Institutes
  • 10.2. Biopharmaceutical Companies
  • 10.3. Diagnostic Laboratories
  • 10.4. Hospitals

11. Minimal Residual Disease Testing Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Minimal Residual Disease Testing Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Minimal Residual Disease Testing Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2024
  • 14.2. FPNV Positioning Matrix, 2024
  • 14.3. Competitive Analysis
    • 14.3.1. Agilus Diagnostics Ltd.
    • 14.3.2. Amgen Inc.
    • 14.3.3. Adaptive Biotechnologies Corporation
    • 14.3.4. ARUP Laboratories
    • 14.3.5. AstraZeneca PLC
    • 14.3.6. Asuragen Inc. by Bio-Techne Corporation
    • 14.3.7. Bio-Rad Laboratories, Inc.
    • 14.3.8. Bristol-Myers Squibb Company
    • 14.3.9. C2I Genomics Inc.
    • 14.3.10. Cergentis B.V.
    • 14.3.11. Exact Sciences Corporation
    • 14.3.12. F. Hoffmann-La Roche Ltd.
    • 14.3.13. Genetron Holdings Limited
    • 14.3.14. GRAIL, LLC by Illumina, Inc.
    • 14.3.15. Guardant Health, Inc.
    • 14.3.16. Integrated DNA Technologies, Inc.
    • 14.3.17. Invivoscribe, Inc.
    • 14.3.18. Kite Pharma, Inc. by Gilead Sciences, Inc.
    • 14.3.19. Laboratory Corporation of America Holdings
    • 14.3.20. Mdxhealth BV
    • 14.3.21. MedGenome Inc
    • 14.3.22. Mission Bio, Inc.
    • 14.3.23. Myriad Genetics, Inc.
    • 14.3.24. Natera Inc.
    • 14.3.25. NeoGenomics Laboratories, Inc.
    • 14.3.26. OPKO Health, Inc.
    • 14.3.27. Quest Diagnostics incorporated
    • 14.3.28. Sysmex Corporation
    • 14.3.29. Veracyte, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 9. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. LATIN AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. EUROPE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. MIDDLE EAST MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASEAN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GCC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPEAN UNION MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. BRICS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. G7 MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. NATO MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. MINIMAL RESIDUAL DISEASE TESTING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 26. MINIMAL RESIDUAL DISEASE TESTING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. MINIMAL RESIDUAL DISEASE TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CHROMOSOMAL MICROARRAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CHROMOSOMAL MICROARRAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CHROMOSOMAL MICROARRAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CHROMOSOMAL MICROARRAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CHROMOSOMAL MICROARRAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CHROMOSOMAL MICROARRAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION (FISH), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION (FISH), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION (FISH), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION (FISH), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION (FISH), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION (FISH), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY MULTI-PARAMETER FLOW CYTOMETRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY MULTI-PARAMETER FLOW CYTOMETRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY MULTI-PARAMETER FLOW CYTOMETRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY MULTI-PARAMETER FLOW CYTOMETRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY MULTI-PARAMETER FLOW CYTOMETRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY MULTI-PARAMETER FLOW CYTOMETRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SINGLE-PARAMETER FLOW CYTOMETRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SINGLE-PARAMETER FLOW CYTOMETRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SINGLE-PARAMETER FLOW CYTOMETRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SINGLE-PARAMETER FLOW CYTOMETRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SINGLE-PARAMETER FLOW CYTOMETRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SINGLE-PARAMETER FLOW CYTOMETRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TARGETED SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TARGETED SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TARGETED SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TARGETED SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY DIGITAL PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY QUANTITATIVE PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY QUANTITATIVE PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY QUANTITATIVE PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY QUANTITATIVE PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY QUANTITATIVE PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY QUANTITATIVE PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA (ALL), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA (ALL), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA (ALL), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA (ALL), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA (ALL), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA (ALL), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY ACUTE MYELOID LEUKEMIA (AML), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY ACUTE MYELOID LEUKEMIA (AML), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY ACUTE MYELOID LEUKEMIA (AML), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY ACUTE MYELOID LEUKEMIA (AML), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY ACUTE MYELOID LEUKEMIA (AML), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY ACUTE MYELOID LEUKEMIA (AML), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY HODGKIN'S LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY HODGKIN'S LYMPHOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY HODGKIN'S LYMPHOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY HODGKIN'S LYMPHOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY HODGKIN'S LYMPHOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY HODGKIN'S LYMPHOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NON-HODGKIN'S LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NON-HODGKIN'S LYMPHOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NON-HODGKIN'S LYMPHOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NON-HODGKIN'S LYMPHOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NON-HODGKIN'S LYMPHOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NON-HODGKIN'S LYMPHOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY MULTIPLE MYELOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY MULTIPLE MYELOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY MULTIPLE MYELOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY MULTIPLE MYELOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BREAST CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2025-2032 (USD MILLION)
  • TABLE 197. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2024 (USD MILLION)
  • TABLE 198. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2025-2032 (USD MILLION)
  • TABLE 199. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2024 (USD MILLION)
  • TABLE 200. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2025-2032 (USD MILLION)
  • TABLE 201. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2025-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2024 (USD MILLION)
  • TABLE 216. NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2025-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2024 (USD MILLION)
  • TABLE 218. NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2025-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2024 (USD MILLION)
  • TABLE 220. NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2025-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2024 (USD MILLION)
  • TABLE 222. NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2025-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2024 (USD MILLION)
  • TABLE 224. NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2025-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2024 (USD MILLION)
  • TABLE 228. NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2025-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2025-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. LATIN AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. LATIN AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2024 (USD MILLION)
  • TABLE 238. LATIN AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2025-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2024 (USD MILLION)
  • TABLE 240. LATIN AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2025-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2024 (USD MILLION)
  • TABLE 242. LATIN AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2025-2032 (USD MILLION)
  • TABLE 243. LATIN AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2024 (USD MILLION)
  • TABLE 244. LATIN AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2025-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2024 (USD MILLION)
  • TABLE 246. LATIN AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2025-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
  • TABLE 248. LATIN AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2025-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2024 (USD MILLION)
  • TABLE 250. LATIN AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2025-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2025-2032 (USD MILLION)

TABLE 2